Dennis Fenton, Ph.D.
Former Executive Vice President, Amgen
Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President. Previously, Dr. Fenton worked as a researcher at Pfizer Central in New Product Development from 1977 to 1981. In addition to his role at AnaptysBio, Dr. Fenton is currently an independent consultant and a member of the boards of directors of Sienna Biopharmaceuticals, Portola Pharmaceuticals, Pfenex Inc., Omniox, Inc., and Modern Meadow, Inc. Dr. Fenton previously served on the boards of directors of Kythera (which was acquired by Allergan in 2015), Hospira (which was acquired by Pfizer in 2015), Dendreon Corp., Xenoport (which was acquired by Arbor Pharmaceuticals in 2016) and Genzyme Corporation (which was acquired by Sanofi Genzyme in 2011). He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.